Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis

J Cyst Fibros. 2011 Jan;10(1):31-6. doi: 10.1016/j.jcf.2010.09.005. Epub 2010 Oct 20.

Abstract

Background: Despite supplementation with standard multivitamins and pancreatic enzymes, deficiencies of vitamins D and K and antioxidants are common in cystic fibrosis (CF).

Methods: In this non-randomized, open-label study, AquADEKs® softgels were given daily over 12 weeks to 14 CF subjects (mean age 15 years, range 10-23) without a preceding wash-out period. Both pancreatic sufficient and insufficient subjects were enrolled. Plasma vitamin and antioxidant levels, urine 8-isoprostane levels, anthropometric measures, and pulmonary function were determined at baseline, 6 and 12 weeks.

Results: Daily supplementation significantly increased plasma beta(β)-carotene, coenzyme Q10, and γ-tocopherol concentrations, decreased proteins induced in vitamin K absence (PIVKA-II) levels, but did not normalize vitamin D and K status in all subjects. Vitamin A levels did not exceed the normal range for any subject during the entire study period. Modest improvements in weight percentile and pulmonary function were observed. Change in plasma β-carotene concentrations weakly correlated with changes in weight and body mass index percentiles.

Conclusions: In this study, AquADEKs® increased systemic antioxidant levels, while maintaining vitamin A levels in the normal range, and improved but did not completely normalize vitamin D and K status. Increased β-carotene levels were associated with improved growth parameters. These results warrant further clinical evaluation in CF.

Trial registration: ClinicalTrials.gov NCT01018303.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antioxidants* / metabolism
  • Antioxidants* / therapeutic use
  • Biomarkers, Pharmacological
  • Body Mass Index
  • Child
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / physiopathology
  • Cystic Fibrosis / therapy*
  • Dietary Supplements / adverse effects
  • Dinoprost / analogs & derivatives
  • Dinoprost / urine
  • Exocrine Pancreatic Insufficiency / complications
  • Exocrine Pancreatic Insufficiency / metabolism
  • Exocrine Pancreatic Insufficiency / therapy*
  • Female
  • Humans
  • Male
  • Oxidative Stress / drug effects
  • Respiratory Function Tests
  • Treatment Outcome
  • Ubiquinone / analogs & derivatives
  • Ubiquinone / blood
  • Ubiquinone / therapeutic use
  • Vitamin A Deficiency / blood
  • Vitamin A Deficiency / etiology
  • Vitamin A Deficiency / therapy*
  • Vitamin D Deficiency / blood
  • Vitamin D Deficiency / etiology
  • Vitamin D Deficiency / therapy*
  • Vitamin K Deficiency / blood
  • Vitamin K Deficiency / etiology
  • Vitamin K Deficiency / therapy*
  • Vitamins* / administration & dosage
  • Vitamins* / adverse effects
  • Vitamins* / pharmacokinetics
  • Young Adult

Substances

  • Antioxidants
  • Biomarkers, Pharmacological
  • Vitamins
  • Ubiquinone
  • 8-epi-prostaglandin F2alpha
  • Dinoprost
  • coenzyme Q10

Associated data

  • ClinicalTrials.gov/NCT01018303